Stay updated on Pembrolizumab + Carboplatin vs Carboplatin in Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Carboplatin vs Carboplatin in Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab + Carboplatin vs Carboplatin in Breast Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedResults have been posted (2025-12-22) and the study plan was updated to include cross-over (Arm Bx) and a revised enrollment target of 76 participants. The endpoints and translational components are described in greater detail, including DCR, PFS, ORR, irRECIST-based assessments, and tumor biomarker analyses.SummaryDifference3%

- Check23 days agoChange DetectedA consolidated Locations section was added with state sites (California, District of Columbia, Illinois, Indiana, Massachusetts, Pennsylvania, Tennessee) and prior state blocks were removed; a new Revision: v3.3.3 tag was introduced.SummaryDifference0.8%

- Check37 days agoChange DetectedDifference0.1%

- Check45 days agoChange DetectedRevision updated to v3.3.2; the previous revision v3.3.1 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check59 days agoChange DetectedThe government funding notice about potential delays and the NIH Clinical Center operating status text has been removed.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab + Carboplatin vs Carboplatin in Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Carboplatin vs Carboplatin in Breast Cancer Clinical Trial page.